SPRB Spruce Biosciences, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$48.38 -3.4%
$133.2M mkt cap
executive summary
Spruce Biosciences, Inc. (SPRB) is a $133.2M company. Revenue is $0 (-100.0% y/y). It is not yet profitable. Our health score is F (23/100). 3 red flags on file. It may need to raise cash (dilution risk).
Revenue (FY)
$0
-100.0% y/y
⛔Going-concern warning
Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
⛔Bankruptcy-risk zone
Altman Z-Score is in the distress zone (-1.35).
⚠Active dilution shelf
An effective S-3 shelf with 4 prospectus filing(s) in 12 months — shares may be getting sold into the market.
who's buying
Insider buys / sells
0 / 0
Cash & ST investments
$54.1M
Operating cash flow
-$33.3M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.